Author: admin

  • Baroness Kinnock of Holyhead – 2016 Parliamentary Question to the Foreign and Commonwealth Office

    Baroness Kinnock of Holyhead – 2016 Parliamentary Question to the Foreign and Commonwealth Office

    The below Parliamentary question was asked by Baroness Kinnock of Holyhead on 2016-01-21.

    To ask Her Majesty’s Government what assessment they have made of the legal opinion recently commissioned by Amnesty International and Saferworld, which claims that they are breaking the law by supplying arms to Saudi

    Baroness Anelay of St Johns

    We are aware of this legal opinion provided on instructions from certain non-governmental organisations. We are also aware of our legal obligations as regards the licensing of arms for export to Saudi Arabia and elsewhere.

    The UK operates one of the most rigorous and transparent arms export control regimes in the world. All arms export licence applications are carefully assessed on a case by case basis against the Consolidated EU and National Arms Export Licensing Criteria, taking intoaccountall relevant information, to ensure compliance with our legal obligations, including under international law. A licence will not be issued, for any country, if to do so would be inconsistent with any provision of the mandatory Criteria. This includes the export of arms to Saudi Arabia. The Government is satisfied that extant licences for Saudi Arabia are compliant with the UK’s export licensing criteria.

  • Baroness Kinnock of Holyhead – 2016 Parliamentary Question to the Foreign and Commonwealth Office

    Baroness Kinnock of Holyhead – 2016 Parliamentary Question to the Foreign and Commonwealth Office

    The below Parliamentary question was asked by Baroness Kinnock of Holyhead on 2016-01-21.

    To ask Her Majesty’s Government what assessment they have made of the evidence available regarding human rights violations committed by the Saudi Arabia-led coalition in Yemen.

    Baroness Anelay of St Johns

    We remain deeply concerned about the human rights situation in Yemen. The UK supported the September UN Human Rights Council resolution which contains mechanisms for monitoring the human rights situation in Yemen. We continue to raise the importance of respect for human rights with all sides of the conflict. We used a wide range of evidence including credible non-governmental organisations, UN agencies and other sources of information to inform our assessment.

  • Baroness Kinnock of Holyhead – 2016 Parliamentary Question to the Foreign and Commonwealth Office

    Baroness Kinnock of Holyhead – 2016 Parliamentary Question to the Foreign and Commonwealth Office

    The below Parliamentary question was asked by Baroness Kinnock of Holyhead on 2016-01-21.

    To ask Her Majesty’s Government what assessment they have made of claims that Saudi Arabia has bombed several hospitals in Yemen, including Médecins Sans Frontières clinics.

    Baroness Anelay of St Johns

    We are aware of recent allegations regarding an attack on a Médecins Sans Frontières (MSF) hospital in Sa’ada province on 10 January. We are also aware of reports of alleged attacks against a MSF hospital in Sa’ada on 26 October and on a MSF unit in Taiz on 2 December. We welcome the public announcement by Saudi Arabia to establish a fact finding committee into the alleged airstrike on the MSF mobile clinic in Taiz. It is important that Saudi Arabia conducts thorough and conclusive investigation into incidents that have raised concerns.

  • Baroness Kinnock of Holyhead – 2016 Parliamentary Question to the Department for Business, Innovation and Skills

    Baroness Kinnock of Holyhead – 2016 Parliamentary Question to the Department for Business, Innovation and Skills

    The below Parliamentary question was asked by Baroness Kinnock of Holyhead on 2016-01-21.

    To ask Her Majesty’s Government what assessment they have made of the response made by human rights groups to figures released by the UK that it sold Saudi Arabia over £1 billion of weapons and air-to-air missiles between July and September 2015.

    Lord Maude of Horsham

    The UK operates one of the most rigorous and transparent export control regimes in the world. No licence would be issued if to do so would contravene the UK’s strict export control criteria. In this case a single licence accounted for 90% of the total value of potential exports authorised by the licences. This was for a long-term contract for the delivery of a new air-to-air munitions capability over a number of years [and is unconnected to current operations by the Royal Saudi Air Force in Yemen.

    Licences granted in a given period do not equate to goods shipped The Department for Business (BIS) export licensing statistics only indicate the number and value of licences granted in a specified period, not the value of actual exports. Licences are usually valid for up to two years and the value of the licence therefore represents an estimate of future export value. As such, the value of licences granted in any one quarter will generally not be the same as the value of goods actually exported and does not provide an indication of goods shipped.

  • Lord Freyberg – 2016 Parliamentary Question to the Department of Health

    Lord Freyberg – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Lord Freyberg on 2016-01-21.

    To ask Her Majesty’s Government what are the costs, rather than the tariff, of a cancer molecular profile using (1) a whole tumour-normal pair using Illumina technology at 70× tumour coverage, and (2) a deep sequenced next-generation sequencing panel test, as deployed in most major NHS teaching hospitals; and if those figures are not available, why not.

    Lord Prior of Brampton

    This information is not held centrally by NHS England. Where the cost of these tests falls outside of tariff, costs will vary according to commissioning arrangements, the systems in place and the technology used.

    Further information on the costs to the National Health Service of whole genome sequencing in cancer and rare diseases will be derived through the 100,000 Genomes Project. The intended NHS re-procurement of Regional Genetic Laboratories will aid in defining the costs of genomic tests.

  • Lord Freyberg – 2016 Parliamentary Question to the Department of Health

    Lord Freyberg – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Lord Freyberg on 2016-01-21.

    To ask Her Majesty’s Government what estimate they have made of how many cancer patients could receive a molecular test on Genomics England’s cancer sequencing budget for 2016 if Genomics England (1) continued to use whole genome sequencing on tumour and normal tissue pairs, and (2) switched to deep sequenced panel tests.

    Lord Prior of Brampton

    The information requested is not yet available. The 100,000 Genomes Project is a research project which is investigating the benefits of whole genome sequencing for patients with cancer and rare diseases. One of the objectives of the Project is to establish the evidence to inform future decisions on National Health Service testing.

    The cancer part of the 100,000 Genomes Project has only recently completed the pilot phase and is incorporating those lessons into routine recruitment of cancer patients. To date, 1,286 tumour and normal genomes have been sequenced and are being interpreted by Genomics England. The pilot phase has involved research participants who have given informed consent, including details about whether there will be feedback of results during the pilot phase. The pilot phase has proved invaluable in understanding the technical requirements for sample preparation and data collection which will be incorporated into the main phase of recruitment in early 2016. As this phase is just starting there is no data on the average turn-around-time or on patient survival.

  • Lord Freyberg – 2016 Parliamentary Question to the Department of Health

    Lord Freyberg – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Lord Freyberg on 2016-01-21.

    To ask Her Majesty’s Government whether the cancer panel test used at the main NHS tertiary hospitals will provide the vast majority of clinically actionable information in a tumour genome, in the light of the NHS reimbursement environment for targeted therapies.

    Lord Prior of Brampton

    A range of cancer panel tests are undertaken by National Health Service trusts. Whether or not these tests capture the majority of clinically actionable information in the tumour genome will not be known until the outcomes from the cancer element of the 100,000 Genomes Project is known.

  • Lord Freyberg – 2016 Parliamentary Question to the Department of Health

    Lord Freyberg – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Lord Freyberg on 2016-01-21.

    To ask Her Majesty’s Government how many successful tumour-normal genomes Genomics England has sequenced, interpreted and returned to patients to date; how long on average it has taken to return those results to patients; and how many cancer patients have died without receiving their results after supplying tumour samples to the 100,000 Genomes Project.

    Lord Prior of Brampton

    The information requested is not yet available. The 100,000 Genomes Project is a research project which is investigating the benefits of whole genome sequencing for patients with cancer and rare diseases. One of the objectives of the Project is to establish the evidence to inform future decisions on National Health Service testing.

    The cancer part of the 100,000 Genomes Project has only recently completed the pilot phase and is incorporating those lessons into routine recruitment of cancer patients. To date, 1,286 tumour and normal genomes have been sequenced and are being interpreted by Genomics England. The pilot phase has involved research participants who have given informed consent, including details about whether there will be feedback of results during the pilot phase. The pilot phase has proved invaluable in understanding the technical requirements for sample preparation and data collection which will be incorporated into the main phase of recruitment in early 2016. As this phase is just starting there is no data on the average turn-around-time or on patient survival.

  • Lord Freyberg – 2016 Parliamentary Question to the Department of Health

    Lord Freyberg – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Lord Freyberg on 2016-01-21.

    To ask Her Majesty’s Government how many (1) definitive, and (2) actionable, diagnoses are made for every 1,000 genomes sequenced as part of the rare disease arm of 100,000 Genomes Project; and how many diagnoses they estimate would have been made if the Project were run using (1) whole, and (2) medical, exome technology; and if those estimates are not available, why not.

    Lord Prior of Brampton

    The 100,000 Genomes Project is not intended to provide definitive or actionable findings from whole genome sequencing. This is the responsibility of the National Health Service Genomic Medicine Centres based on interpretation reports provided by Genomics England. To date approximately 20 reports have been issued based on the initial interpretation of the pilot phase genome data. It is not possible to estimate the comparison between whole genome and exome methods for these patients. That is because the eligibility criteria for patients to be invited to participate in the 100,000 Genomes Project require that they remain undiagnosed after standard NHS diagnostic tests.

  • Lord Freyberg – 2016 Parliamentary Question to the Department of Health

    Lord Freyberg – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Lord Freyberg on 2016-01-21.

    To ask Her Majesty’s Government what are the costs per test in rare disease treatment using (1) whole genome, (2) whole exome, and (3) medical exome, sequencing; and if those figures are not available, why not.

    Lord Prior of Brampton

    This information is not held centrally by NHS England or the UK Genetic Testing Network. Where the cost of these tests falls outside of tariff, costs will vary according to commissioning arrangements, the systems in place and the technology used.

    The cost of whole genome sequencing will continue to change in line with advances in technology. Costs will also need to be defined and include full bioinformatics analysis and clinical interpretation which is likely to be more costly than the sequencing itself.